Sanofi Wins Dismissal Of Securities Action
A federal judge has dismissed a putative securities class action against Sanofi-Aventis alleging that the French drug company made misrepresentations regarding the side effects of anti-obesity drug rimonabant during clinical trials....To view the full article, register now.
Already a subscriber? Click here to view full article